Luiz Paulo Chaves Souza

Mr. Luiz Paulo Chaves Souza

Medical School of Ribeirão Preto - USP
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2021 in Genes
Verified
Journal Article
Open access
PDF file
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
CMCamila Melo
Camila Melo
FSFabiano Pinto Saggioro
Fabiano Pinto Saggioro
RPRodolfo Reis PI
Rodolfo Reis PI
JSJeremy Andrew Squire
Jeremy Andrew Squire
Prostate cancers may reactivate a latent embryonic program called the epithelial–mesenchymal transition (EMT) during the development of metastatic disease. Through EMT, tumors can develop a mesenchymal phenotype similar to cancer stem cell traits that contributes to metastasis and variation in therapeutic responses. Some of the recurrent somatic mutations of prostate cancer affect EMT driver genes and effector transcription factors that induce the chromatin- and androgen-dependent epigenetic alterations that characterize castrate-resistant prostate cancer (CRPC). EMT regulators in prostate cancer comprise transcription factors (SNAI1/2, ZEB1, TWIST1, and ETS), tumor suppressor genes (RB1, PTEN, and TP53), and post-transcriptional regulators (miRNAs) that under the selective pressures of antiandrogen therapy can develop an androgen-independent metastatic phenotype. In prostate cancer mouse models of EMT, Slug expression, as well as WNT/β-Catenin and notch signaling pathways, have been shown to increase stemness potential. Recent single-cell transcriptomic studies also suggest that the stemness phenotype of advanced prostate cancer may be related to EMT. Other evidence correlates EMT and stemness with immune evasion, for example, activation of the polycomb repressor complex I, promoting EMT and stemness and cytokine secretion through RB1, TP53, and PRC1. These findings are helping clinical trials in CRPC that seek to understand how drugs and biomarkers related to the acquisition of EMT can improve drug response.

Verified
Journal Article
Open access
PDF file
CMCamila Melo
Camila Melo
TVThiago Vidotto
Thiago Vidotto
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
WLWilliam Lautert-Dutra
William Lautert-Dutra
RPRodolfo Reis PI
Rodolfo Reis PI
JSJeremy Andrew Squire
Jeremy Andrew Squire
Immunotherapy has improved patient survival in many types of cancer, but for prostate cancer, initial results with immunotherapy have been disappointing. Prostate cancer is considered an immunologically excluded or cold tumor, unable to generate an effective T-cell response against cancer cells. However, a small but significant percentage of patients do respond to immunotherapy, suggesting that some specific molecular subtypes of this tumor may have a better response to checkpoint inhibitors. Recent findings suggest that, in addition to their function as cancer genes, somatic mutations of PTEN, TP53, RB1, CDK12, and DNA repair, or specific activation of regulatory pathways, such as ETS or MYC, may also facilitate immune evasion of the host response against cancer. This review presents an update of recent discoveries about the role that the common somatic mutations can play in changing the tumor microenvironment and immune response against prostate cancer. We describe how detailed molecular genetic analyses of the tumor microenvironment of prostate cancer using mouse models and human tumors are providing new insights into the cell types and pathways mediating immune responses. These analyses are helping researchers to design drug combinations that are more likely to target the molecular and immunological pathways that underlie treatment failure.

16 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
WLWilliam Lautert-Dutra
William Lautert-Dutra
CMCamila Melo
Camila Melo
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
CCCheryl Crozier
Cheryl Crozier
FSFabiano P. Saggioro
Fabiano P. Saggioro
JSJeremy Andrew Squire
Jeremy Andrew Squire
Background: CDK12 inactivation is a predictive biomarker for immune checkpoint blockers (ICB) treatment response in advanced prostate cancer (PCa), but some CDK12-altered patients fail to respond to ICB. Downregulation of MHC expression has been described as a mechanism of intrinsic and acquired resistance to ICB in various cancers, but there is little information on whether MHC expression levels are altered in CDK12 defective PCa that fails to respond to ICB treatments. Methods: Using genomics data of primary and metastatic prostate cancer from two public domain cohorts and a retrospective cohort, we investigated variation in the expression of the MHC genes and associated downstream changes in CDK12 mutated patients. The findings of public domain data were validated using transcriptomic data from a 53-patient retrospective cohort from our Institute. Results: Based on the analysis of gene expression quartiles, we divided the tumors into “High” and “Low” expression levels of MHC-I and -II. CDK12 defective tumors with increased MHC levels showed the activation of several pathways associated with the immune system and elevated PD - L1 , IDO1 , and TIM3 expression. These transcriptomic findings were confirmed using expression analyses of our cohort of 53 primary PCa. There was an increased composition of CD8+ T cells, B cells, γδ T cells, and M1 Macrophages in CDK12 mutated tumors with elevated MHC levels based on digital cytometric analyses. In contrast, CDK12 defective tumors with decreased MHC expression were often subject to loss of heterozygosity (LOH) genomic events affecting MHC-I/-II and the HLA gene cluster on chromosome 6. CDK12 defective PCa expresses higher levels of classical MHC, has an active and inflamed tumor microenvironment, and increases the presence of effector T cells. Conclusions: Reduced MHC expression may be caused by the acquisition of specific somatic genomic events that reduce the expression of antigen presentation genes. Combining CDK12 mutation, MHC expression levels, and LOH status may better predict outcomes for ICB-eligible PCa. In addition, these findings draw attention to the need to investigate therapeutic approaches for enhancing MHC expression in CDK12 defective PCa to improve ICB responses.

8 March 2022
Verified
Book Chapter
Closed access
PDF file
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
CMC. M. Melo
C. M. Melo
WLW. Lautert-Dutra
W. Lautert-Dutra
ACA. L. Caliari
A. L. Caliari
JSJeremy Andrew Squire
Jeremy Andrew Squire

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
ACAndré Luiz Caliari
André Luiz Caliari
WLWilliam Lautert-Dutra
William Lautert-Dutra
FSFrancisco Cesar Souza Silva
Francisco Cesar Souza Silva
CMCamila Morais Melo
Camila Morais Melo
JSJeremy Andrew Squire
Jeremy Andrew Squire
Prostate cancer (PCa) reactivates a latent embryonic program called epithelial-mesenchymal transition during disease progression. The mesenchymal phenotype contributes to invasion, metastasis and therapy response variation. In this study, we characterize the downstream effects of ZEB1 expression based on cohort dichotomization of quartiles of expression comparing the 25% of tumors with high ZEB1 expression to the 75% of tumors with lower ZEB1 expression. Differential gene expression (DGE), gene set enrichment analysis (GSEA) and immune cell abundance prediction were accessed using PCa expression data from TCGA (n=488). ZEB1 high status based on gene expression was stratified based on ZEB1 expression values higher than the 3rd expression quartile value (n=122). Contingency analysis showed that PTEN loss is more frequent in the ZEB1 high group (Chi-square, p=0.0005) which supports previously presented data from our group that showed an inverse correlation between ZEB1 and PTEN protein expression but showed no difference between the groups regarding presence of the TMPRSS2-ERG fusion. DGE showed that more than 13,000 genes are differentially expressed in the ZEB1 high group while GSEA showed that signaling pathways such as HALLMARK TGF BETA, HALLMARK IL2 STAT5, HALLMARK INFLAMMATORY RESPONSE and HALLMARK NOTCH were upregulated in the ZEB1 high group compared to the low group. Yet inflammatory response related pathways were observed enriched in the ZEB1 high group, CIBERSORT analysis showed that effector immune cells such as CD8+ T cells and T helper cells (Holm-Sidak, p=000003 and p=0.000613, respectively) were enriched in the ZEB1 low group in comparison to the ZEB1 high group, which supports previous studies that suggest that ZEB1 cooperates with PTEN loss and TMPRSS2-ERG fusion to promote an immune evasive phenotype in PCa. Collectively, these findings demonstrate that gene expression changes associated with increased ZEB1 expression may involve clinically relevant pathways such as modulation of the tumor immune microenvironment and NOTCH-dependent tumor progression. Citation Format: Luiz Paulo Chaves, André Luiz Caliari, William Lautert-Dutra, Francisco Cesar Souza Silva, Camila Morais Melo, Fabiano Pinto Saggioro, Rodolfo Borges dos Reis, Jeremy Andrew Squire. Analysis of the impact of ZEB1 expression on pathway enrichment and immune cell abundance in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6098.

15 June 2022 in Cancer Research
Verified
Journal Article
Open access
WLWilliam Lautert-Dutra
William Lautert-Dutra
CMCamila Morais Melo
Camila Morais Melo
Luiz Paulo Chaves SouzaLuiz Paulo Chaves Souza
Luiz Paulo Chaves Souza
ACAndré Luiz Caliari
André Luiz Caliari
FSFrancisco Cesar Souza Silva
Francisco Cesar Souza Silva
JSJeremy Andrew Squire
Jeremy Andrew Squire
Prostate Cancer (PCa) is considered an immunologically excluded tumor, unable to generate an effective T-cell response against cancer cells. Inactivating mutations of the PTEN tumor suppressor are one of the most common events in human malignancies that contribute to tumorigenesis by affecting many cancer Hallmark pathways. The CDK12, RB1, TP53, AR and ZEB1 genes have been variously implicated in pathways of PCa progression and immune evasion. Here, we present a comprehensive analysis of The Cancer Genome Atlas derived PCa cohort (n=488, 96 homozygous and 64 hemizygous PTEN loss). Differential gene expression (DGE) and pathway enrichment analysis were performed for all five genes using the DESeq2 tool from the Bioconductor package for R. All comparisons were designed to compensate for gene expression changes caused by PTEN loss (Table 1). Functional pathway analysis showed that fusion positive samples presented several downregulated pathways, including leukocyte mediated cytotoxicity, IFN type I response and IFN-γ production. AR high presented upregulation of pathways such as DNA replication and chromatin remodeling, while AR low presented upregulation of pathways such as T cell activation and lymphocyte proliferation. ZEB1 high presented a wide range of enriched pathways, including upregulation of mesenchymal cell differentiation and T cell activation. CDK12-Hom group exhibited upregulation of T cell activation, T cell differentiation and IFN-γ production. TP53 mutation revealed upregulation of various pathways including DNA replication and cell division. RB1 loss showed enrichment of pathways such as T cell activation and lymphocyte activation. Our analysis showed that variation in these five genes can promote gene expression changes associated with clinically relevant pathways independently of PTEN and that AR, CDK12, TMPRSS2-ERG fusion, ZEB1 and RB1 status are potential biomarkers for immunotherapy response. Citation Format: William Lautert-Dutra, Camila Morais Melo, Luiz Paulo Chaves, André Luiz Caliari, Francisco Cesar Souza Silva, Jeremy Andrew Squire. Differential gene expression related to TMPRSS2-ERG fusion, CDK12, RB1, TP53, AR and ZEB1 based on transcriptomic analysis of the TCGA PRAD cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6099.